{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:14:00Z","timestamp":1794334440200,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The renoprotective effects of urate-lowering therapy, especially with selective urate reabsorption inhibitors (SURIs), remain to be established in patients with chronic kidney disease (CKD). This study compared changes in the estimated glomerular filtration rate (eGFR) slope associated with the initiation of dotinurad (a SURI) versus febuxostat (a xanthine oxidase inhibitor) in patients with chronic kidney disease, mainly due to diabetic kidney disease or hypertensive nephrosclerosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a single-center retrospective cohort study of 81 adult CKD patients with hyperuricemia who were newly started on dotinurad (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200931) or febuxostat (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200950) between January 2020 and October 2023. The primary endpoint was the change in the annual eGFR slope in the 1-year period before and after therapy initiation, which was evaluated via a linear mixed-effects model adjusted for baseline differences and confounders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      According to the multivariable-adjusted analyses, the change in the eGFR slope differed significantly between the two groups (interaction term for group \u00d7 period \u00d7 time,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.048). In the dotinurad group, a declining eGFR trend of \u2212\u20092.8 mL\/min\/1.73\u00a0m\u00b2 per year (95% confidence interval [CI] \u2212\u20096.0 to +\u20090.4) before treatment stabilized to +\u20091.4 mL\/min\/1.73\u00a0m\u00b2 per year (95% CI \u2212\u20091.0 to +\u20093.7) after one year of therapy. This within-group change (+\u20094.2 mL\/min\/1.73\u00a0m\u00b2 per year) was statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021). No comparable change was observed in the febuxostat group, whose eGFR slope changed from \u2212\u20090.3 (95% CI \u2212\u20093.0 to +\u20092.5) to \u2212\u20090.8 (95% CI \u2212\u20092.6 to +\u20091.0) mL\/min\/1.73\u00a0m\u00b2 per year (within-group change \u2212\u20090.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.731). This difference in slopes accounted for the overall difference in treatment effects between the two therapies. The proportion of patients who achieved the target serum uric acid concentration\u2009&lt;\u20096.0\u00a0mg\/dL at 12 months did not differ significantly between the groups, nor did the incidence of a\u2009\u2265\u200930% decline in the eGFR during follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this CKD cohort, the initiation of dotinurad was associated with a more favorable change in the eGFR slope compared with febuxostat. However, considering the observational nature and the small sample size, these findings should be regarded as hypothesis-generating. Further large-scale studies are warranted to confirm these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-04937-7","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:57:57Z","timestamp":1775836677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of dotinurad versus febuxostat on the one-year eGFR slope in CKD patients with hyperuricemia: a retrospective cohort study"],"prefix":"10.1186","volume":"27","author":[{"given":"Hikaru","family":"Uematsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Toida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Joki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"4937_CR1","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Jalal D, S\u00e1nchez-Lozada LG, Kang D, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transpl. 2013;28:2221\u20138. https:\/\/doi.org\/10.1093\/ndt\/gft029.","journal-title":"Nephrol Dial Transpl"},{"key":"4937_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ekir.2022.11.016","volume":"8","author":"RJ Johnson","year":"2022","unstructured":"Johnson RJ, Sanchez Lozada LG, Lanaspa MA, Piani F, Borghi C. Uric Acid and Chronic Kidney Disease: Still More to Do. Kidney Int Rep. 2022;8:229. https:\/\/doi.org\/10.1016\/j.ekir.2022.11.016.","journal-title":"Kidney Int Rep"},{"key":"4937_CR3","doi-asserted-by":"publisher","first-page":"382918","DOI":"10.1155\/2015\/382918","volume":"2015","author":"C Giordano","year":"2015","unstructured":"Giordano C, Karasik O, King-Morris K, Asmar A. Uric Acid as a Marker of Kidney Disease: Review of the Current Literature. Dis Markers. 2015;2015:382918. https:\/\/doi.org\/10.1155\/2015\/382918.","journal-title":"Dis Markers"},{"key":"4937_CR4","doi-asserted-by":"publisher","first-page":"12394","DOI":"10.3390\/ijms222212394","volume":"22","author":"Y Kimura","year":"2021","unstructured":"Kimura Y, Tsukui D, Kono H. Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. Int J Mol Sci. 2021;22:12394. https:\/\/doi.org\/10.3390\/ijms222212394.","journal-title":"Int J Mol Sci"},{"key":"4937_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2015.11.026","volume":"29","author":"M Kanbay","year":"2016","unstructured":"Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C, et al. Uric acid in metabolic syndrome: From an innocent bystander to a central player. Eur J Intern Med. 2016;29:3\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2015.11.026.","journal-title":"Eur J Intern Med"},{"key":"4937_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis. 2018;72:798\u2013810. https:\/\/doi.org\/10.1053\/j.ajkd.2018.06.028.","journal-title":"Am J Kidney Dis"},{"key":"4937_CR7","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al. Effects of Allopurinol on the Progression of Chronic Kidney Disease. N Engl J Med. 2020;382:2504\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1915833.","journal-title":"N Engl J Med"},{"key":"4937_CR8","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, et al. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020;382:2493\u2013503. https:\/\/doi.org\/10.1056\/NEJMoa1916624.","journal-title":"N Engl J Med"},{"key":"4937_CR9","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105:S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"key":"4937_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10157-019-01818-2","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clin Exp Nephrol. 2020;24:53\u201361. https:\/\/doi.org\/10.1007\/s10157-019-01818-2.","journal-title":"Clin Exp Nephrol"},{"key":"4937_CR11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","volume":"3","author":"K Ichida","year":"2012","unstructured":"Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764. https:\/\/doi.org\/10.1038\/ncomms1756.","journal-title":"Nat Commun"},{"key":"4937_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12882-020-01953-z","volume":"21","author":"H Guan","year":"2020","unstructured":"Guan H, Zheng Y, Zhou X, Xu Y, Fu C, Xiao J, et al. Efficacy of different urinary uric acid indicators in patients with chronic kidney disease. BMC Nephrol. 2020;21:290. https:\/\/doi.org\/10.1186\/s12882-020-01953-z.","journal-title":"BMC Nephrol"},{"key":"4937_CR13","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1038\/s41598-024-55809-9","volume":"14","author":"Y Asahina","year":"2024","unstructured":"Asahina Y, Sakaguchi Y, Oka T, Hattori K, Kawaoka T, Doi Y, et al. Association between urinary uric acid excretion and kidney outcome in patients with CKD. Sci Rep. 2024;14:5119. https:\/\/doi.org\/10.1038\/s41598-024-55809-9.","journal-title":"Sci Rep"},{"key":"4937_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12882-024-03535-9","volume":"25","author":"H Amano","year":"2024","unstructured":"Amano H, Kobayashi S, Terawaki H. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease. BMC Nephrol. 2024;25:97. https:\/\/doi.org\/10.1186\/s12882-024-03535-9.","journal-title":"BMC Nephrol"},{"key":"4937_CR15","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.2147\/DDDT.S416025","volume":"17","author":"K Yanai","year":"2023","unstructured":"Yanai K, Hirai K, Kaneko S, Mutsuyoshi Y, Kitano T, Miyazawa H, et al. The Efficacy and Safety of Dotinurad on Uric Acid and Renal Function in Patients with Hyperuricemia and Advanced Chronic Kidney Disease: A Single Center, Retrospective Analysis. Drug Des Devel Ther. 2023;17:3233\u201348. https:\/\/doi.org\/10.2147\/DDDT.S416025.","journal-title":"Drug Des Devel Ther"},{"key":"4937_CR16","unstructured":"Japanese Society of Nephrology. Evidence-based clinical practice guideline for chronic kidney disease 2023. Tokyo Igakusha; 2023."},{"key":"4937_CR17","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"key":"4937_CR18","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1681\/ASN.2019010008","volume":"30","author":"ME Grams","year":"2019","unstructured":"Grams ME, Sang Y, Ballew SH, Matsushita K, Astor BC, Carrero JJ, et al. Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. J Am Soc Nephrol. 2019;30:1746\u201355. https:\/\/doi.org\/10.1681\/ASN.2019010008.","journal-title":"J Am Soc Nephrol"},{"key":"4937_CR19","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, et al. GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. J Am Soc Nephrol. 2019;30:1735\u201345. https:\/\/doi.org\/10.1681\/ASN.2019010007.","journal-title":"J Am Soc Nephrol"},{"key":"4937_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/biomedicines11020567","volume":"11","author":"H Yanai","year":"2023","unstructured":"Yanai H, Katsuyama H, Hakoshima M, Adachi H. Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study. Biomedicines. 2023;11:567. https:\/\/doi.org\/10.3390\/biomedicines11020567.","journal-title":"Biomedicines"},{"key":"4937_CR21","doi-asserted-by":"publisher","first-page":"8990","DOI":"10.1038\/s41598-025-94020-2","volume":"15","author":"T Takata","year":"2025","unstructured":"Takata T, Taniguchi S, Mae Y, Kageyama K, Fujino Y, Iyama T, et al. Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia. Sci Rep. 2025;15:8990. https:\/\/doi.org\/10.1038\/s41598-025-94020-2.","journal-title":"Sci Rep"},{"key":"4937_CR22","doi-asserted-by":"publisher","unstructured":"Motomura T, Higashi M, Hattori A, Akiyama R, Kai H. Efficacy and safety of dotinurad in patients with advanced chronic kidney disease. Intern Med. 2025. https:\/\/doi.org\/10.2169\/internalmedicine.5834-25.","DOI":"10.2169\/internalmedicine.5834-25"},{"key":"4937_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s10157-023-02419-w","volume":"28","author":"O Kurihara","year":"2024","unstructured":"Kurihara O, Yamada T, Kato K, Miyauchi Y. Efficacy of dotinurad in patients with severe renal dysfunction. Clin Exp Nephrol. 2024;28:208\u201316. https:\/\/doi.org\/10.1007\/s10157-023-02419-w.","journal-title":"Clin Exp Nephrol"},{"key":"4937_CR24","doi-asserted-by":"publisher","first-page":"e115210","DOI":"10.1371\/journal.pone.0115210","volume":"9","author":"D Verzola","year":"2014","unstructured":"Verzola D, Ratto E, Villaggio B, Parodi EL, Pontremoli R, Garibotto G, et al. Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4. PLoS ONE. 2014;9:e115210. https:\/\/doi.org\/10.1371\/journal.pone.0115210.","journal-title":"PLoS ONE"},{"key":"4937_CR25","doi-asserted-by":"publisher","first-page":"2424834","DOI":"10.1080\/10641963.2024.2424834","volume":"46","author":"J Ouyang","year":"2024","unstructured":"Ouyang J, Wang H, Gan Y, Huang J. Uric acid mediates kidney tubular inflammation through the LDHA\/ROS\/NLRP3 pathway. Clin Exp Hypertens. 2024;46:2424834. https:\/\/doi.org\/10.1080\/10641963.2024.2424834.","journal-title":"Clin Exp Hypertens"},{"key":"4937_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12967-022-03629-8","volume":"20","author":"Y Lu","year":"2022","unstructured":"Lu Y, Zhang Z, Wu H, Fang L, Hu B, Tang C, et al. SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease. J Transl Med. 2022;20:420. https:\/\/doi.org\/10.1186\/s12967-022-03629-8.","journal-title":"J Transl Med"},{"key":"4937_CR27","doi-asserted-by":"publisher","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","volume":"316","author":"A Novikov","year":"2019","unstructured":"Novikov A, Fu Y, Huang W, Freeman B, Patel R, van Ginkel C, et al. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Ren Physiol. 2019;316:F173\u201385. https:\/\/doi.org\/10.1152\/ajprenal.00462.2018.","journal-title":"Am J Physiol Ren Physiol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04937-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04937-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04937-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:47:49Z","timestamp":1781646469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04937-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4937"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04937-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7994599\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Toho University Ohashi Medical Center (Approval No. H24050). The requirement for informed consent was waived because of the retrospective design; an opt-out consent process was used as described. All methods were carried out in accordance with the Declaration of Helsinki and relevant guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (no individual personal data are presented in this article).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"322"}}